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SUMMARY. Albinterferon alfa-2b (albIFN) is a fusion protein of
recombinant human albumin/recombinant interferon (IFN)-
a-2b, with 200-h half-life. Safety/efficacy of albIFN q4wk
was evaluated in 391 treatment-naive patients with chronic
hepatitis C virus (HCV) genotype 2/3. Patients were ran-
domized 3:4:4:4 to one of four open-label treatment groups:
pegylated IFN (Peg-IFN)-a-2a 180 lg qwk or albIFN 900,
1200 or 1500 lg q4wk, plus oral ribavirin 800 mg/day, for
24 weeks. Primary efficacy endpoint was sustained virologic
response (SVR; HCV RNA <20 IU/mL 24 weeks post-treat-
ment). SVR rates were as follows: 85%, 76%, 76% and 78%
with Peg-IFNa-2a and albIFN 900, 1200 and 1500 lg,
respectively (P = NS); corresponding rapid virologic response
rates (HCV RNA <43 IU/mL at week 4) were as follows: 78%,
49% (P < 0.001), 60% (P = 0.01) and 71%. SVR rates were
not influenced by interleukin 28B genotype, although rapid
virologic response rates were greater with interleukin 28B CC
(P = NS). Serious adverse event rates were as follows: 4%,
11%, 3% and 3% with Peg-IFNa-2a and albIFN 900, 1200
and 1500 lg, respectively. No increase in serious/severe
respiratory events was noted with albIFN. Fewer absolute
neutrophil count reductions <750/mm3 occurred with albI-
FN (P = 0.03), leading to fewer IFN dose reductions. Hae-
moglobin reductions <10 g/dLwere less frequent with albIFN
900 and 1200 lg vs 1500 lg and Peg-IFNa-2a (P = 0.02),
leading to fewer ribavirin dose reductions. albIFN adminis-
tered q4wk produced fewer haematologic reductions than
Peg-IFNa-2a, but had numerically lower SVR rates (P = NS)
in patients with chronic HCV genotype 2/3.
Keywords: albinterferon alfa-2b, hepatitis C virus, interferon,
sustained virologic response.
INTRODUCTION
Hepatitis C virus (HCV) is endemic in most parts of the world,
with an estimated overall prevalence of 3% (or 170 million
infected individuals), and is a frequent cause of liver disease,
including liver failure and hepatocellular carcinoma [1].
HCV genotypes (Gt) 2 and 3 represent 20–40% of chronic
HCV infections in North America and Western Europe, and
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60% in Southeast Asia [2]. Twenty-four-week combination
therapy with pegylated interferon (Peg-IFN)-a injected once
weekly (qwk) plus daily oral ribavirin (RBV) has become the
standard of care for treatment of chronic HCV Gt 2 or 3 [3].
Pegylated IFNa injections are, however, associated with
postinjection symptoms such as chills, fever, myalgia,
arthralgia, fatigue and headache, which often necessitate
concomitant therapy with antipyretics and analgesics. In
addition, weekly injections create a burden for the patient
with respect to convenience, fear of self-injection and travel
when the treatment needs to be administered at a healthcare
centre. Fewer injections may, therefore, be an important
factor in the decision to undergo treatment and in adherence
to therapy.
Albinterferon alfa-2b (albIFN) is a fusion polypeptide of
recombinant human albumin and recombinant IFNa-2b,
with a half-life of 8 days and IFNa-like pharmacodynamic
properties [4]. A phase 2 dose-ranging study, in which
patients with chronic HCV Gt 1 received two albIFN injec-
tions (200–1200 lg) 14 days apart, demonstrated that
albIFN levels were consistently detectable 28 days after the
second injection and antiviral activity was maintained with
the higher dose [5]. Recent phase 3 studies of albIFN 900
and 1200 lg injected every 2 week (q2wk) in combination
with RBV showed efficacy similar to Peg-IFNa-2a for the
treatment of chronic HCV Gt 1 or 2/3 [6,7]. In the phase 3
studies, increased rates of pulmonary adverse events (AEs)
were noted with albIFN, including interstitial lung disease,
compared with those seen with Peg-IFNa. In this study,
lower doses of albIFN were investigated, and respiratory
assessments were performed prospectively to assess whether
any respiratory signals were present when injection fre-
quency was reduced. In addition, albIFN was investigated as
a once-every-4-wk (q4wk) regimen with the aim of further
reducing injection burden and improving treatment conve-
nience over standard qwk therapy with Peg-IFNa.
METHODS
Study oversight
This study was designed, implemented and reported in
accordance with the ICH Harmonized Tripartite Guidelines
for Good Clinical Practice, with applicable local regulations
and with the ethical principles laid down in the Declaration
of Helsinki. The institutional review boards of participating
centres approved the study protocol. All patients provided
written informed consent. Novartis Pharma AG (Basel,
Switzerland) and Human Genome Sciences, Inc. (Rockville,
MD, USA) sponsored the study. Novartis was responsible for
collection and statistical analysis of the data. A trial steering
committee comprising study investigators provided input to
the protocol and oversight of the conduct of the study, and
an independent data-monitoring committee was responsible
for ongoing review of safety data during the study. The
authors had full access to the data, wrote this manuscript
and take responsibility for the accuracy of the reported
analysis.
Patient selection
Adult patients (aged ‡18 years) were enrolled in the study if
they had chronic HCV Gt 2 or 3 and had not previously
received IFNa therapy. Patients were excluded if they had
decompensated liver disease or other causes of chronic liver
disease, thrombocytopenia (<90 000 platelets/mm3), neu-
tropenia (<1500 neutrophils/mm3), history of moderate–
severe psychiatric disease, immunologically mediated
disease, uncontrolled thyroid disease, clinical evidence of
pre-existing interstitial or other severe lung diseases (by
pulmonary function testing and chest X-rays at screening),
co-infection with hepatitis B virus or HIV, a significant
coexisting medical condition, or alcohol or drug dependence.
Study design
This phase 2b, randomized, multicentre, active-controlled,
open-label, dose-ranging study was conducted at 53 centres
in 10 countries (Australia, Canada, Germany, India, Italy,
Poland, Spain, Taiwan, Thailand and UK) between October
2008 and May 2009 (ClinicalTrials.gov identifier NCT0075
9200). The median number of patients enrolled per site was
5 (range 1–33).
A centralized randomization assigned patients in a 3:4:4:4
ratio, in blocks of 15, to 1 of 4 treatment groups: active
control Peg-IFNa-2a (PEGASYS; Hoffmann-La Roche Inc,
Basel, Switzerland) 180 lg qwk (24 subcutaneous injec-
tions) and albIFN 900, 1200 and 1500 lg q4wk (six sub-
cutaneous injections/group). The initial design included the
option of evaluating albIFN 1800 lg q4wk (and additional
Peg-IFNa-2a controls, leading to an overall 5:4:4:4:4 ran-
domization) after an interim review of the 6-month data
from the lower doses by the data-monitoring committee.
This option was not pursued because of the anticipated
absence of additional efficacy benefit from the highest albIFN
dose, and therefore, only the three lower doses were inves-
tigated. All patients were to receive oral RBV 800 mg/day in
two divided doses (RIBASPHERE; Three Rivers Pharmaceu-
ticals, Warrendale, PA, USA). At baseline, all eligible
patients were randomized using an interactive voice
response system (IVRS). Investigators called the IVRS after
confirming that patients fulfilled all the inclusion/exclusion
criteria. The IVRS assigned randomization numbers to
patients, which were used to assign patients to a treatment
group. Randomization numbers were not communicated to
callers and were generated using the following procedure to
ensure that treatment assignment was unbiased: a patient
randomization list was produced by the IVRS provider using
a validated system that automated the random assignment
of patient numbers to randomization numbers. These
 2012 Blackwell Publishing Ltd
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randomization numbers were linked to the different treat-
ment arms, which in turn were linked to medication num-
bers. A separate medication randomization list was produced
by Novartis Drug Supply Management using a validated
system that automated the random assignment of medica-
tion numbers to medication packs containing each of the
study drugs. The randomization scheme for patients was
reviewed and approved by a member of the Novartis Bio-
statistics Quality Assurance Group.
Randomization was stratified by HCV Gt (2 or 3) and
pretreatment serum HCV RNA level (£ or >800 000 IU/mL).
Treatment duration was 24 weeks, with 24-week follow-up.
The study protocol specified stepwise (‡1 level) dose reduc-
tions of albIFN (steps down to 1200, 900, 700 and 500 lg)
and Peg-IFNa-2a (steps down to 135, 90 and 45 lg) to
manage haematologic abnormalities and moderate–severe
AEs. The use of haematopoietic growth factors was not
permitted.
Blood samples for the interleukin 28B (IL28B) single-
nucleotide polymorphism rs12979860 Gt were collected
retrospectively following the description by Ge et al. [8] of an
association between the IL28B Gt and response to IFN
therapy. Patients had to provide additional written informed
consent for this test, and samples were obtained in one-third
of the study population (n = 117).
Efficacy assessments
The primary efficacy endpoint was sustained virologic
response (SVR), defined as HCV RNA < limit of detection
(LOD; 20 IU/mL) at 24 weeks after the end of therapy.
Secondary efficacy endpoints were rapid virologic response
at week 4 (RVR), defined as HCV RNA < limit of quantifi-
cation (LOQ; 43 IU/mL); early virologic response at week 12
(EVR), defined as HCV RNA <LOQ or >2-log HCV RNA
reduction; and end-of-treatment response (ETR), defined as
HCV RNA <LOD at the end of treatment. Assessment of HCV
RNA levels was accomplished using real-time polymerase
chain reaction (CE-marked COBAS AmpliPrep/COBAS
TaqMan HCV test; Roche Diagnostics, Basel, Switzerland).
Viral kinetics
Assessments of HCV RNA were conducted in all patients at
baseline, weeks 1, 2, 4, 12 and 24 on treatment, and weeks
4, 12 and 24 post-treatment. Intensive viral kinetics were
examined in a subset of 38 patients with samples taken
postdose at 12 and 24 h, days 3 and 8 and weeks 2, 3, 4, 6,
8, 10 and 12. All samples were obtained predose on injection
days.
Safety assessments
Safety was assessed by physical examination and laboratory
tests during treatment and through 24 weeks after comple-
tion of therapy to document resolution of any ongoing AEs.
Dose reductions of one or both drugs were permitted for
clinically significant AEs or laboratory abnormalities. A
single dose of albIFN or up to five doses of Peg-IFNa-2a could
be withheld before discontinuation of the patient from the
study. The severity of AEs was graded using the Division of
Microbiology and Infectious Diseases toxicity rating scale [9].
Statistical methods
Because the primary objective of the study was to assess the
safety and tolerability of the albIFN q4wk regimens, sample
size was chosen based on the power to detect treatment-
related AEs rather than statistical power for hypothesis
testing. With 100 patients per albIFN treatment group, the
probability of observing ‡1 AE with an underlying rate of 2%
was >80%.
All analyses were performed in the intention-to-treat (ITT)
population, defined as the subset of all randomized patients
who received ‡1 dose of study agent. Adherence to IFN and
RBV therapy was calculated as the total dose received/
planned (based on 24 weeks of planned full-dose treatment)
and expressed as a percentage. All statistical tests were two
sided and performed at the 5% level of significance. All
analyses were performed using SAS 9 statistical software
(SAS Institute Inc., Cary, NC, USA). The SVR and on-treat-
ment response rates for each treatment group, and the
differences between each albIFN group and the Peg-IFNa-2a
group were estimated with 95% confidence intervals. Sta-
tistical testing was performed using Pearson chi-square test
(or Fishers exact test when >20% of expected contingency
table cell counts were <5). Safety was reported, and overall
comparisons were made by treatment group.
RESULTS
Patient disposition and demographics
In all, 623 patients were screened, 391 were randomized,
and 388 received ‡1 dose of study medication, constituting
the ITT population (Fig. 1). Patient demographics and dis-
ease characteristics were similar among treatment groups
(Table 1). About half of patients were enrolled in Asian
countries, and most (72%) had HCV Gt 3. Using the
rs12979860 tag single-nucleotide polymorphism, the IL28B
Gt was recorded in 117 patients: 61 (52.1%) had the CC Gt,
52 (44.4%) had CT, and 4 (3.4%) had TT. Patients from
Taiwan had a higher frequency of the IL28B CC Gt (28/31;
90.3%) than those from Western countries (33/86; 38.4%),
a geographic distribution that may be reflected in the higher
frequency of the IL28B CC Gt in patients with HCV Gt 2 (41/
61; 67.2%) vs Gt 3 (20/56; 35.7%). This is a result of the
increased frequency of Gt 2 in the Asian patients. Liver
histology was not assessed in this study following standard
treatment guidelines for the HCV Gt 2/3 population [3].
 2012 Blackwell Publishing Ltd
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Efficacy
The SVR rates in the ITT population were 84.6%, 75.5%,
75.7% and 78.1% with Peg-IFNa-2a 180 lg qwk and albIFN
900, 1200 and 1500 lg q4wk, respectively (P = NS;
Fig. 2). Rapid virologic responses occurred in a dose-depen-
dent fashion in the three albIFN groups, with lower rates
than with Peg-IFNa-2a (49.0% [P < 0.001], 60.2%
[P = 0.01] and 70.5% with albIFN 900, 1200 and 1500 lg,
respectively, vs 78.2%). The EVR and ETR rates were high in
all patients. Virologic breakthrough (HCV RNA levels >LOQ
on treatment after having previously achieved levels <LOD)
was observed in one patient each in the Peg-IFNa-2a and
albIFN 1200-lg groups, but not in the other albIFN groups.
Relapse rates ranged from 13.3% to 18.1%.
Viral kinetics
Viral load decline at week 2 was significantly greater with
albIFN 1200 lg (P = 0.003) and 1500 lg (P = 0.01) than
with Peg-IFNa-2a (Fig. 3). At week 4, all albIFN groups
had lesser declines than did the Peg-IFNa-2a group, the
difference reaching statistical significance with albIFN
900 lg (P = 0.001), reflecting the differences in RVR
rates. Viral load changes between baseline and week 12,
however, were similar, in line with EVR rates across all
groups.
In the 38-patient subgroup with intensive viral kinetics,
the pattern of viral load decline was comparable to that of
the overall population between weeks 4 and 12. During the
first 4 weeks, viral load decline was greater with Peg-IFNa-
2a at weeks 2, 3 and 4 than with albIFN 900 lg. After the
second albIFN 900-ug injection at week 4, viral suppression
was similar to that with Peg-IFNa-2a and the other albIFN
doses.
Baseline predictors of sustained virologic response
In general, SVR rates by patient subgroup reflected the dif-
ferences between treatment arms observed in the overall
population (Table S1). As expected, SVR rates were higher in
younger patients and those with HCV Gt 2, baseline HCV
RNA <800 000 IU/mL, low c-glutamyl transpeptidase at
baseline and lower body weight. In harder-to-treat patients
with HCV Gt 3 and baseline HCV RNA >800 000 IU/mL,
SVR rates (range 66–74%) were 10% lower than that of
the whole population.
Interleukin 28B genetic variation and virologic response
In the subset of 117 patients with IL28B genetic testing, the
IL28B genetic variation did not affect baseline viral load:
72.1% of patients with the CC Gt had a baseline HCV RNA
level >800 000 IU/mL vs 64.3% with a non-CC Gt
Fig. 1 Study disposition. AE, adverse event; albIFN, albinterferon alfa-2b; HCV, hepatitis C virus; Peg-IFNa-2a, pegylated
interferon-a-2a; EVR, early virologic response at week 12.
 2012 Blackwell Publishing Ltd
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(P = NS). There was no difference in overall SVR rates
between patients with the CC Gt (50/61; 82.0%) and CT or
TT Gt (44/56; 78.6%; P = NS), and no difference within
treatment groups (Table 2). Virologic response rates did not
differ between the 117 patients with IL28B genetic testing
and the 271 who were not genotyped: 62.4% vs 64.2% for
RVR and 80.3% vs 77.1% for SVR. The IL28B genetic
variation did not demonstrate a consistent effect on RVR.
Overall, RVR rates were 67.2% vs 57.1% in patients with vs
without the CC Gt (P = NS). Within treatment groups, dif-
ferences in RVR between patients with and without the CC
Gt were not consistent and were limited by the small sample
size. In multivariate analyses, the IL28B Gt was not identi-
fied as a significant factor of virologic response. Significant
variables for RVR and SVR were viral load at baseline, HCV
Gt and HCV disease duration, as well as albIFN 900-lg
q4wk vs Peg-IFNa-2a 180-lg qwk treatment group for RVR
only and patient age for SVR only (Table 3). Because of the
low number of patients who did not achieve RVR and were
also tested for the IL28B Gt (3 with Peg-IFNa-2a), it could
not be determined whether the host IL28B Gt was a
predictor of response in this patient subset, as previously
reported [10].
On-treatment predictors of sustained virologic response
Rapid virologic response, as well as HCV RNA <LOD at week
2 or 4, had a high positive predictive value for SVR in all
treatment groups (Table S2). The negative predictive value
of RVR for SVR was, however, lower with albIFN 900 lg
(40.4%) and 1200 lg (46.3%) than with albIFN 1500 lg
(54.8%) or Peg-IFNa-2a (52.9%).
Table 1 Patient baseline characteristics
Peg-IFNa-2a
180 lg qwk
(n = 78)
albIFN 900 lg
q4wk
(n = 102)
albIFN
1200 lg q4wk
(n = 103)
albIFN
1500 lg q4wk
(n = 105)
Age
Mean ± SD, years 43.3 (11.4) 42.2 (12.4) 43.2 (12.0) 41.3 (11.3)
‡45 years, n (%) 42 (53.8) 43 (42.2) 46 (44.7) 46 (43.8)
Race, n (%)
Caucasian 36 (46.2) 46 (45.1) 41 (39.8) 51 (48.6)
Asian 39 (50.0) 53 (52.0) 60 (58.3) 50 (47.6)
Other 3 (3.9) 3 (2.9) 1 (2.0) 4 (3.8)
Ethnicity, n (%)
Chinese: Taiwan 9 (11.5) 12 (11.8) 17 (16.5) 18 (17.1)
Indian: subcontinent 17 (21.8) 25 (24.5) 24 (23.3) 18 (17.1)
Other Asian: Thailand 13 (16.7) 16 (15.7) 19 (18.4) 14 (13.3)
Male sex, n (%) 50 (64.1) 66 (64.7) 65 (63.1) 57 (54.3)
Body wt ‡ 75 kg, n (%) 32 (41.0) 40 (39.2) 34 (33.0) 38 (36.2)
BMI ‡ 25 kg/m2, n (%)* 44 (56.4) 52 (51.0) 38 (36.9) 44 (41.9)
HCV Gt, n (%)
2 22 (28.2) 30 (29.4) 28 (27.2) 30 (28.6)
3 56 (71.8) 72 (70.6) 75 (72.8) 75 (71.4)
IL28B Gt
CC 9/21 (42.9) 17/33 (51.5) 18/32 (56.3) 17/31 (54.8)
CT 11/21 (52.4) 16/33 (48.5) 13/32 (40.6) 12/31 (38.7)
TT 1/21 (4.8) 0/33 (0) 1/32 (3.1) 2/31 (6.5)
Mean disease duration ± SD, years 4.0 (5.39) 4.7 (5.64) 4.7 (5.32) 4.5 (4.70)
HCV RNA ‡800 000 IU/mL, n (%) 46 (59.0) 66 (64.7) 70 (68.0) 66 (62.9)
ALT > 1.5 · ULN, n (%) 51 (65.4) 61 (59.8) 55 (53.4) 59 (56.2)
GGT £ ULN, n (%)* 48 (61.5) 73 (71.6) 75 (72.8) 85 (81.0)
albIFN, albinterferon alfa-2b; ALT, alanine aminotransferase; BMI, body mass index; GGT, c-glutamyl transpeptidase; Gt,
genotype; HCV, hepatitis C virus; IL28B, interleukin 28B; Peg-IFNa-2a, pegylated interferon-a-2a; SD, standard deviation;
ULN, upper limit of normal. *P < 0.05; 2-sided P-value for comparison of treatment groups obtained from Pearson chi-square
test or Fishers exact test.
 2012 Blackwell Publishing Ltd
albIFN q4wk for chronic HCV genotype 2/3 627
Adherence to therapy
Adherence was high in all treatment groups, with 85.9–
95.1% of patients achieving ‡80% adherence to both IFN
and RBV treatment (Table S3). Fewer patients had IFN dose
reductions with all albIFN doses than with Peg-IFNa-2a
180 lg qwk, and fewer RBV dose reductions occurred with
albIFN 900 and 1200 lg q4wk. The proportions of patients
with ‡80% adherence to IFN were higher with albIFN
(92.2–98.0%) than with Peg-IFNa-2a (88.5%; P = 0.05),
although the proportions of patients with ‡80% adherence
to RBV were similar in all treatment groups (89.5–95.1%).
Overall, 3.8%, 5.8%, 5.8% and 6.7% of patients with Peg-
IFNa-2a and albIFN 900, 1200 and 1500 lg, respectively,
did not complete the study.
Adverse events
Adverse events leading to dose reduction or interruption of
IFN or RBV were less frequent with albIFN 900 lg q4wk
than with Peg-IFNa-2a 180 lg qwk (P = 0.03; Table 4).
The numerically higher rate of patients with a serious AE in
the albIFN 900-lg group (10.8%) than in the Peg-IFNa-2a
(3.8%) and albIFN 1200-lg (2.9%) and 1500-lg (2.9%)
groups was because of the high number of post-treatment
serious AEs (six of 11; Table 5). One death was reported in
the study with albIFN 1200 lg because of intentional nar-
cotic overdose.
The rates of neutropenia <750 and <500/mm3 were
significantly lower with albIFN 900 lg q4wk than with
Peg-IFNa-2a 180 lg qwk (5.0% vs 17.9% [P = 0.03] and
1.0% vs 9.0% [P = 0.01], respectively; Table 4); a similar
trend was observed with the other albIFN doses. Anaemia
(haemoglobin <10 g/dL) was also less frequent with albIFN
900 lg (11.9%) and 1200 lg (18.4%) than with Peg-IFNa-
2a (25.6%; overall comparison P = 0.02). The reduced
frequency of haematologic AEs led to fewer albIFN dose
reductions.
The common AEs associated with albIFN treatment were
those typically observed with IFNa (Table 4). The
incidence rates of pyrexia and alopecia were higher with
albIFN than with Peg-IFNa-2a. A dose–response relation-
ship was noted in the albIFN groups for alopecia, but not
for pyrexia. A trend for a lower incidence of AEs was seen
with albIFN 900 lg q4wk vs Peg-IFNa-2a 180 lg qwk for
fatigue and asthenia. Most other AEs had similar incidence
rates across treatment groups. These common AEs were
mostly mild in severity and rapidly reversible after treat-
ment termination.
Pulmonary adverse events
Rates of cough were similar with Peg-IFNa-2a and albIFN
900 and 1200 lg, but higher with 1500 lg (Table 4).
Dyspnoea was reported in 11.3% of patients and exertional
dyspnoea in 7.0%, with no difference between treatment
(a)
(b)
Fig. 2 Virologic response (a, intention-
to-treat population) and relapse rates
(b). Relapse defined as hepatitis C virus
(HCV) < limit of detection (20 IU/mL) at
end of treatment and becoming detect-
able at post-treatment visit. aP <0.001;
bP = 0.01. albIFN, albinterferon alfa-2b;
ETR, end-of-treatment response (HCV
RNA < limit of detection); EVR, early
virologic response at week 12 (HCV
RNA < limit of quantification [43 IU/
mL] or >2-log reduction); Peg-IFNa-2a,
pegylated interferon-a-2a; RVR, rapid
virologic response at week 4 (HCV RNA
< limit of quantification); q4wk, once
every 4 weeks; qwk, once every week;
SVR, sustained virologic response
24 weeks after treatment (HCV RNA
< limit of detection).
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groups. Most of these common pulmonary AEs were of mild
intensity, and no severe case was reported.
Four serious pulmonary AEs occurred with albIFN vs none
with Peg-IFNa-2a. Three cases of pneumonia occurred with
albIFN 900 lg – one of which led to treatment discontinu-
ation – and one with 1200 lg, whereas none was reported
with albIFN 1500 lg or Peg-IFNa-2a (Table 5). All cases of
pneumonia resolved after appropriate therapy. One case of
Table 2 Interleukin 28B genetic variation and treatment response
Peg-IFNa-2a
180 lg qwk
(n = 21)
albIFN
900 lg q4wk
(n = 33)
albIFN
1200 lg q4wk
(n = 32)
albIFN
1500 lg q4wk
(n = 31)
Total
(n = 117)
RVR, n (%)
CC 9/9 (100) 8/17 (47.1) 10/18 (55.6) 14/17 (82.4) 41/61 (67.2)
Non-CC 9/12 (75.0) 7/16 (43.8) 10/14 (71.4) 6/14 (42.9) 32/56 (57.1)
CT 8/11 (72.7) 7/16 (43.8) 9/13 (69.2) 5/12 (41.7) 29/52 (55.8)
TT 1/1 (100.0) 0/0 (0) 1/1 (100.0) 1/2 (50,0) 3/4 (75.0)
SVR, n (%)
CC 8/9 (88.9) 13/17 (76.5) 14/18 (77.8) 15/17 (88.2) 50/61 (82.0)
Non-CC 10/12 (83.3) 14/16 (87.5) 9/14 (64.3) 11/14 (78.6) 44/56 (78.6)
CT 9/11 (81.8) 14/16 (87.5) 9/13 (69.2) 9/12 (75) 41/52 (78.8)
TT 1/1 (100) 0/0 0/1 (0.0) 2/2 (100) 3/4 (75.0)
albIFN, albinterferon alfa-2b; Peg-IFNa-2a, pegylated interferon-a-2a; RVR, rapid virologic response at week 4; SVR, sustained
virologic response.
(a)
(b)
Fig. 3 Mean hepatitis C virus (HCV)
RNA (log10 IU/mL) by week in (a)
overall intention-to-treat population
and (b) subset of 38 patients with
intensive viral pharmacokinetics.
albIFN, albinterferon alfa-2b; FU,
follow-up; LOD, limit of detection; LOQ,
limit of quantitation; Peg-IFNa-2a,
pegylated interferon-a-2a; q4wk, once
every 4 weeks; qwk, once every week.
 2012 Blackwell Publishing Ltd
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restrictive lung disease – reported at week 12 with albIFN
1500 lg – led to treatment discontinuation and reversed
after the end of treatment.
DISCUSSION
High rates of on- and post-treatment virologic responses
were observed in all treatment groups, although SVR rates
were greater with Peg-IFNa-2a 180 lg qwk. The RVR rates
were significantly lower with albIFN q4wk, particularly
when comparing 900 and 1200 lg with Peg-IFNa-2a qwk;
however, these differences resulted in smaller differences in
SVR rates than may have been expected from the differences
in RVR. The results obtained with albIFN q4wk showed
similar EVR, ETR and SVR rates to those reported in the
phase 3 ACHIEVE-2/3 trial with albIFN q2wk in patients
with HCV Gt 2/3 [6]. In that study, however, patients
treated with albIFN 900 lg q2wk achieved a similar RVR
rate to that with Peg-IFNa-2a 180 lg qwk in comparison
with the lower, dose-dependent rates observed with albIFN
q4wk in the present study. In an earlier phase 2 study of
albIFN q4wk in patients with HCV Gt 1, a similar pattern
was noted, with lower RVR rates and similar, but numeri-
cally lower, SVR rates compared with Peg-IFNa-2a qwk [11].
The differential effect of albIFN on RVR compared with
Peg-IFNa-2a may be explained by the pharmacokinetic
profile that follows albIFN q4wk administration [5]. The
lower plasma IFN exposure occurring at week 4 with albIFN
q4wk vs albIFN q2wk or Peg-IFNa-2a qwk may delay
achievement of HCV RNA negativity compared with more
frequent injections. A delay in achieving initial HCV RNA
undetectability results in a shorter overall duration of HCV
RNA negativity on treatment, a factor associated with the
likelihood of achieving an SVR [12]. The differential in RVR
rates may, therefore, play some role in the SVR imbalance
observed in this study. This finding raises questions regard-
ing the intensity of the initial antiviral pressure obtained
with a q4wk regimen, and the potential benefit of increasing
the frequency of albIFN injections over the first 4 weeks of
treatment to bolster the initial virologic response to equal
that attained by the standard of care, followed by an albIFN
q4wk regimen for the remainder of the treatment course.
This hypothesis is supported by the higher week-2 virologic
response rates, but lower RVR rates with albIFN q4wk in this
study, which may be the result of attenuation of antiviral
effect with the q4wk regimen. The impact of increasing RVR
rates by increasing dosing in the first 4 weeks of therapy
remains controversial. Studies in both Gt 1 and 2/3 have
Table 3 Multivariate analysis of association of RVR and SVR with treatment and baseline characteristics (n = 117)*
Parameter
Parameter
estimate SE Odds ratio (95% CI) P-value
RVR
Intercept 3.2171 0.8741 <.001
Treatment: albIFN 1500 lg q4wk
vs Peg-IFNa-2a 180 lg qwk
)1.3098 0.7912 0.27 (0.06, 1.27) 0.10
Treatment: albIFN 1200 lg q4wk vs
Peg-IFNa-2a 180 lg qwk
)1.1045 0.7928 0.33 (0.07, 1.57) 0.16
Treatment: albIFN 900 lg q4wk vs
Peg-IFNa-2a 180 lg qwk
)2.3517 0.7944 0.10 (0.02, 0.45) 0.003
HCV disease duration, years )0.0777 0.0372 0.93 (0.86, 1.00) 0.04
Gt 2 vs 3 1.0923 0.4523 2.98 (1.23, 7.23) 0.02
Baseline HCV RNA ‡800 000 IU/mL )1.8236 0.5677 0.16 (0.05, 0.49) 0.001
SVR
Intercept 4.0705 0.9654 <0.001
Age ‡ vs <45 years )2.0063 0.6751 0.13 (0.04, 0.50) 0.003
HCV disease duration, years )0.0819 0.0406 0.92 (0.85, 1.00) 0.04
Gt 2 vs 3 1.7099 0.5897 5.53 (1.74, 17.56) 0.004
Baseline HCV RNA ‡800 000 IU/mL )1.8314 0.8084 0.16 (0.03, 0.78) 0.02
albIFN, albinterferon alfa-2b; CI, confidence interval; Gt, genotype; HCV, hepatitis C virus; Peg-IFNa-2a, pegylated interferon-a-
2a ; RVR, rapid virologic response at week 4; SE, standard error; SVR, sustained virologic response. Covariates tested in model:
interleukin 28B single-nucleotide polymorphism rs12979860 Gt (CC, CT and TT); treatment group Peg-IFNa-2a 180 lg qwk
and albIFN 900, 1200 and 1500 lg q4wk); age (‡ vs <45 years); sex (male vs female); HCV Gt 2 vs 3; body weight (‡ vs
<75 kg); body mass index (‡ vs <25 kg/m2); smoking status (current vs not current smoker); alcohol use (history vs no history
of alcohol use); baseline alanine transaminase (> vs £1.5 · upper limit of normal); baseline c-glutamyl transpeptidase (> vs £
upper limit of normal); region (Asian vs non-Asian); baseline HCV RNA (‡ vs <800 000 IU/mL); and HCV disease duration
(years). *Subgroup with interleukin 28B genetic testing.
 2012 Blackwell Publishing Ltd
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shown that RVR is the most powerful on-treatment predictor
of response [13], although IFN induction studies have
shown that enhanced initial on-treatment response rates
may not improve SVR rates [14]. The impact of IFN-induced
early virologic responses in the evolving era of direct-acting
antiviral therapies associated with high RVR rates, such as
boceprevir and telaprevir, remains to be elucidated [15,16].
The IL28B Gt was not a predictor of SVR in this chronic
HCV Gt 2/3 cohort, in contrast to previous findings in
patients with chronic HCV Gt 1 [8]. In two recent studies,
the IL28B Gt was associated with RVR, but as in the present
study, not with SVR [17,18]. In a separate study of Italian
patients infected with HCV Gt 2/3, the IL28B Gt was a
predictor of SVR in the 78 patients who failed to achieve an
RVR [10]. In the present study, small patient numbers with
available IL28B genotyping and failure to achieve an RVR
precluded similar analysis. Larger patient cohorts stratified
according to ethnicity are required to determine the influ-
ence of IL28B on HCV viral kinetics and virologic response
following IFN/RBV-based therapy in Gt 2 and 3.
The overall incidence of AEs was high (>90%) and similar
across treatment groups, with similar types of AEs. There
was, however, a trend for more frequent severe AEs with
albIFN, and the incidence of serious AEs was significantly
higher with albIFN than with Peg-IFNa-2a. Unlike in pre-
vious albIFN studies, the rates of cough were the same across
Table 4 Adverse events and dose reductions or interruptions because of adverse events
Peg-IFNa-2a
180 lg qwk
(n = 78), n (%)
albIFN
900 lg q4wk
(n = 102), n (%)
albIFN
1200 lg q4wk
(n = 103), n (%)
albIFN
1500 lg q4wk
(n = 105), n (%) P-value*
‡1 AE 76 (97.4) 95 (93.1) 97 (94.2) 102 (97.1) 0.44
‡1 serious AE 3 (3.8) 11 (10.8) 3 (2.9) 3 (2.9) 0.03
‡1 severe AE 6 (7.7) 14 (13.7) 15 (14.6) 14 (13.3) 0.53
AE leading to IFN/RBV
discontinuation
2 (2.6) 3 (2.9) 3 (2.9) 6 (5.7) 0.69
AE leading to dose reduction/
interruption
22 (28.2) 15 (14.7) 19 (18.4) 35 (33.3) 0.006
Death 0 0 1 (1.0) 0 0.73
Haematologic/total AEs (%)
Neutrophil count
<750/mm3 14/78 (17.9) 5/101 (5.0) 14/103 (13.6) 9/105 (8.6) 0.03
<500/mm3 7/78 (9.0) 1/101 (1.0) 2/103 (1.9) 1/105 (1.0) 0.009
Haemoglobin
<10.0 g/dL 20/78 (25.6) 12/101 (11.9) 19/103 (18.4) 30/105 (28.6) 0.02
<8.5 g/dL 4/78 (5.1) 1/101 (1.0) 1/103 (1.0) 7/105 (6.7) 0.045
Platelets
<50 000/mm3 5/78 (6.4) 2/100 (2.0) 3/103 (2.9) 1/105 (1.0) 0.19
<25 000/mm3 2/78 (2.6) 0/100 0/103 0/105 0.04
Common AEs (‡20% in any group)
Alopecia 24 (30.8) 44 (43.1) 46 (44.7) 59 (56.2) 0.008
Pyrexia 26 (33.3) 49 (48.0) 46 (44.7) 49 (46.7) 0.20
Headache 29 (37.2) 34 (33.3) 44 (42.7) 37 (35.2) 0.54
Fatigue 29 (37.2) 33 (32.4) 35 (34.0) 30 (28.6) 0.66
Decreased appetite 21 (26.9) 28 (27.5) 29 (28.2) 26 (24.8) 0.95
Insomnia 21 (26.9) 26 (25.5) 27 (26.2) 26 (24.8) 0.99
Myalgia 20 (25.6) 24 (23.5) 27 (26.2) 23 (21.9) 0.93
Cough 16 (20.5) 24 (23.5) 22 (21.4) 31 (29.5) 0.44
Pruritus 19 (24.4) 25 (24.5) 17 (16.5) 23 (21.9) 0.49
Asthenia 15 (19.2) 13 (12.7) 24 (23.3) 21 (20.0) 0.27
Anaemia 17 (21.8) 13 (12.7) 13 (12.6) 29 (27.6) 0.01
Influenza-like illness 16 (20.5) 20 (19.6) 12 (11.7) 23 (21.9) 0.23
Nausea 14 (17.9) 16 (15.7) 22 (21.4) 17 (16.2) 0.71
AE, adverse event; albIFN, albinterferon alfa-2b; IFN, interferon; Peg-IFNa-2a, pegylated interferon-a-2a; RBV, ribavirin. *Two-
sided P-value for comparison of treatment groups obtained from Pearson chi-square or Fishers exact test for categorical data,
or 1-way analysis of variance for continuous data. Including 1 post-treatment serious AE in Peg-IFNa-2a 180-lg qwk group
and six in albIFN 900-ug q4wk group; Death by heroin overdose.
 2012 Blackwell Publishing Ltd
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treatment groups [6,7]. As in the earlier trials, more respi-
ratory infections and a case of restrictive lung disease were
noted with albIFN treatment, although similar AEs are
known to occur with Peg-IFNa, as well [19,20]. The
persistent numeric imbalance in serious pulmonary AEs
observed with albIFN vs Peg-IFNa across trials, however,
creates concern regarding the pulmonary safety of the
albIFN molecule. (Note: a full analysis of the changes in
pulmonary function and respiratory effects of both albIFN
and Peg-IFNa-2a in the present trial has been submitted for
separate publication.) Alopecia and pyrexia rates were
higher with albIFN vs Peg-IFNa-2a. The lower frequency of
injections with albIFN q4wk was, however, associated with
lower anaemia and neutropenia rates, and thus fewer IFN
dose reductions than with Peg-IFNa-2a qwk. Overall, the
900-lg dose provided the best safety profile of the albIFN
treatment groups. The improvement in haematologic profile
appears to be related to the pharmacokinetic profile of albIFN
q4wk, with the longer interval between injections allowing
for recovery from IFN-induced bone marrow suppression.
Although the albIFN doses used in this q4wk study were
lower on a monthly average than the 900-lg q2wk dose
used in the ACHIEVE-2/3 trial [6], pyrexia and alopecia rates
remained higher than with Peg-IFNa-2a 180 lg qwk with-
out a dose–response, suggesting that peak serum albIFN
concentration may have driven these AEs rather than
average concentration. Alopecia rates were higher in all
albIFN groups than with Peg-IFNa-2a; whether alopecia
rates were driven by peak serum concentration or were
because of an intrinsic property or tissue distribution of the
albIFN molecule is not clear.
While the focus of antiviral therapy for chronic HCV is
projected by some to ultimately move away from IFN-based
therapies, IFN-free regimens have not yet been developed
beyond early trials [21]. Interferon may be required to
diminish resistance to direct-acting antiviral agents, and an
IFN platform with a reduced frequency of injections may be
an important strategy if efficacy can be maintained with an
improved AE profile. The present study demonstrates the
ability to reduce the frequency of albIFN injections from
q2wk to q4wk in a chronic HCV Gt 2/3 population with a
small, statistically insignificant reduction in efficacy. It
remains to be determined whether the combination of long-
acting IFNs administered q4wk with direct-acting antiviral
agents or intensification of IFN exposure in the first 4 weeks
of therapy can overcome the reduction in efficacy seen in the
present study.
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